Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Ann Thorac Surg. 2011 Sep;92(3):1044-50. doi: 10.1016/j.athoracsur.2011.04.029.
Activating enhancer-binding protein-2β (AP2β) is a transcription factor involved in apoptosis. The purpose of the current study was to assess the cellular location and level of AP2β in non-small cell lung cancer (NSCLC) and normal lung tissue and investigate whether the level and localization of AP2β expression is predictive of overall survival in patients with stage I NSCLC.
We performed immunohistochemical analysis of tissue microarrays (TMAs) prepared from stage I NSCLC specimens with adjacent normal lung tissue from two independent sets of patients who underwent lung resection with curative intent at our institution. The AP2β intensity was assessed in TMAs, and AP2β staining patterns were classified as either diffuse or nucleolar in the TMAs. The AP2β intensity and localization were analyzed for correlation with patients' survival.
Immunohistochemical analysis of TMAs showed that the intensity of AP2β immunohistochemical staining did not correlate with overall survival. When location of AP2β was analyzed in TMAs, all of the normal lung tissue had diffuse pattern of AP2β. In the first set of NSCLC, patients with nucleolar pattern had a significantly lower 5-year survival rate than patients with diffuse pattern (67% versus 100%; p=0.004); this finding was confirmed in the second set (64% versus 91%; p=0.02). Multivariate analysis revealed that nucleolar pattern was an independent predictor of poor overall survival in both sets.
The AP2β, which is located in the nucleoplasm in normal lung tissue, is found in either nucleoplasm or nucleoli in NSCLC. The patients with AP2β in the nucleoli had poor survival compared with patients with AP2β in the cytoplasm.
激活增强子结合蛋白-2β（AP2β）是一种参与细胞凋亡的转录因子。本研究旨在评估非小细胞肺癌（NSCLC）和正常肺组织中 AP2β 的细胞位置和水平，并探讨 AP2β 表达水平和定位是否可预测 I 期 NSCLC 患者的总生存率。
我们对来自本机构接受根治性肺切除术的两个独立患者组的 I 期 NSCLC 标本及其相邻正常肺组织进行了组织微阵列（TMA）的免疫组织化学分析。在 TMA 中评估 AP2β 强度，并将 AP2β 染色模式分类为弥漫性或核仁性。分析 AP2β 强度和定位与患者生存的相关性。
TMA 的免疫组织化学分析显示，AP2β 免疫组织化学染色强度与总生存率无关。当分析 TMA 中 AP2β 的位置时，所有正常肺组织均具有弥漫性 AP2β 模式。在第一组 NSCLC 中，核仁模式患者的 5 年生存率明显低于弥漫性模式患者（67%比 100%；p=0.004）；这一发现在第二组中得到了证实（64%比 91%；p=0.02）。多变量分析显示，核仁模式是两组患者总生存不良的独立预测因子。
AP2β 位于正常肺组织的核质中，在 NSCLC 中位于核质或核仁中。与胞质中存在 AP2β 的患者相比，核仁中存在 AP2β 的患者生存较差。
